A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

NCT02552953 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Cyclacel Pharmaceuticals, Inc.